A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7

Trial Profile

A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2018

At a glance

  • Drugs Vestronidase alfa (Primary)
  • Indications Mucopolysaccharidosis VII
  • Focus Adverse reactions
  • Sponsors Ultragenyx Pharmaceutical
  • Most Recent Events

    • 01 Jun 2018 Planned End Date changed from 1 Feb 2019 to 1 Jan 2019.
    • 01 Jun 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019.
    • 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top